EUR/JPY bounces back from recent lows after Trump indicates reduced tensions in the Middle East
EUR/JPY Recovers from Lows Amid Shifting Geopolitical Sentiment
The EUR/JPY currency pair has bounced back from its earlier session lows, though it still trades 0.30% lower on Monday, hovering around 183.65 as the Japanese Yen (JPY) weakens slightly in response to signs of easing geopolitical tensions.
Initially, the pair faced downward pressure as escalating conflict in the Middle East increased demand for traditional safe-haven currencies. Market mood improved, however, after remarks from US President Donald Trump—reported by Reuters—hinted at a possible reduction in hostilities with Iran. Trump mentioned that the US and Iran had held “very good and productive conversations” over the past two days, raising hopes for a diplomatic solution.
Trump further revealed that he had directed the Department of War to delay any military action against Iranian energy targets for five days, contingent on the progress of ongoing talks. This development prompted investors to scale back their safe-haven bets, causing the Yen to retreat and allowing EUR/JPY to recover some lost ground.
Despite the pair’s rebound, caution prevails as the geopolitical landscape remains unpredictable. Any setback in negotiations could quickly renew demand for the Yen and other defensive assets.
Domestic Developments in Japan
Within Japan, officials continue to emphasize their readiness to intervene if currency markets become excessively volatile. Atsushi Mimura, Japan’s chief foreign exchange official, reiterated the government’s commitment to maintaining stability. Meanwhile, the Bank of Japan (BoJ) maintains a relatively firm policy stance, with Governor Kazuo Ueda suggesting that further interest rate increases are possible if economic trends warrant such action.
Eurozone Factors and Upcoming Events
In Europe, the Euro (EUR) is being shaped by a mix of influences. Higher energy costs in the Eurozone are fueling inflation expectations, which supports the European Central Bank’s (ECB) preference for tighter policy. The ECB has recently noted that ongoing geopolitical uncertainties have made the economic outlook much less predictable, highlighting increased risks for inflation and potential headwinds for growth.
Looking ahead, investors are awaiting a speech from ECB Chief Economist Philip Lane later on Monday, as well as Japan’s Consumer Price Index (CPI) data due Tuesday. These events are expected to influence monetary policy expectations and could drive further movement in the EUR/JPY pair.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
